Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

Item
http://www.wikidata.org/entity/Q33400793
Molecular therapeutics in pancreas cancerEpitope-specific mechanisms of IGF1R inhibition by ganitumabA randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Can we unlock the potential of IGF-1R inhibition in cancer therapy?A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewImpact of targeting insulin-like growth factor signaling in head and neck cancers.XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerThe angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Promising new therapies in advanced pancreatic adenocarcinomas.Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.Met, IGF1R, and other new targets in upper GI malignancies.Trial watch: Monoclonal antibodies in cancer therapy
P2860

Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

Item
http://www.wikidata.org/entity/Q33400793
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Safety and pharmacokinetics of ...... ts with advanced solid tumors.
@ast
Safety and pharmacokinetics of ...... ts with advanced solid tumors.
@en
type
label
Safety and pharmacokinetics of ...... ts with advanced solid tumors.
@ast
Safety and pharmacokinetics of ...... ts with advanced solid tumors.
@en
prefLabel
Safety and pharmacokinetics of ...... ts with advanced solid tumors.
@ast
Safety and pharmacokinetics of ...... ts with advanced solid tumors.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Safety and pharmacokinetics of ...... nts with advanced solid tumors
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-11-3369
P407
P433
P478
P50
P577
P698